Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Investments (2022 - 2025)

Historic Long-Term Investments for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $11.5 million.

  • Corvus Pharmaceuticals' Long-Term Investments fell 2407.98% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year decrease of 2407.98%. This contributed to the annual value of $12.5 million for FY2024, which is 2222.29% down from last year.
  • Corvus Pharmaceuticals' Long-Term Investments amounted to $11.5 million in Q3 2025, which was down 2407.98% from $11.8 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Long-Term Investments' 5-year high stood at $33.4 million during Q1 2022, with a 5-year trough of $11.5 million in Q3 2025.
  • Its 4-year average for Long-Term Investments is $18.5 million, with a median of $16.1 million in 2023.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Long-Term Investments crashed by 4030.35% in 2023, and later tumbled by 1104.15% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Long-Term Investments (Quarter) stood at $21.9 million in 2022, then fell by 26.3% to $16.1 million in 2023, then dropped by 22.22% to $12.5 million in 2024, then fell by 8.05% to $11.5 million in 2025.
  • Its Long-Term Investments stands at $11.5 million for Q3 2025, versus $11.8 million for Q2 2025 and $12.1 million for Q1 2025.